Unravelling heterogeneous effects of cancer‑associated fibroblasts on poor prognosis markers in breast cancer EM‑G3 cell line: In vitro‑targeted treatment (anti‑IL-6, anti‑VEGF-A, anti‑MFGE8) based on transcriptomic profiling

Oncol Rep. 2024 Jan;51(1):3. doi: 10.3892/or.2023.8662. Epub 2023 Nov 17.

Abstract

Breast cancer is the most frequently diagnosed cancer in women worldwide. Although dramatically increased survival rates of early diagnosed cases have been observed, late diagnosed patients and metastatic cancer may still be considered fatal. The present study's main focus was on cancer‑associated fibroblasts (CAFs) which is an active component of the tumor microenvironment (TME) regulating the breast cancer ecosystem. Transcriptomic profiling and analysis of CAFs isolated from breast cancer skin metastasis, cutaneous basal cell carcinoma, and squamous cell carcinoma unravelled major gene candidates such as IL6, VEGFA and MFGE8 that induced co‑expression of keratins‑8/‑14 in the EM‑G3 cell line derived from infiltrating ductal breast carcinoma. Western blot analysis of selected keratins (keratin‑8, ‑14, ‑18, ‑19) and epithelial‑mesenchymal transition‑associated markers (SLUG, SNAIL, ZEB1, E‑/N‑cadherin, vimentin) revealed specific responses pointing to certain heterogeneity of the studied CAF populations. Experimental in vitro treatment using neutralizing antibodies against IL-6, VEGF‑A and MFGE8 attenuated the modulatory effect of CAFs on EM‑G3 cells. The present study provided novel data in characterizing and understanding the interactions between CAFs and EM‑G3 cells in vitro. CAFs of different origins support the pro‑inflammatory microenvironment and influence the biology of breast cancer cells. This observation potentially holds significant interest for the development of novel, clinically relevant approaches targeting the TME in breast cancer. Furthermore, its implications extend beyond breast cancer and have the potential to impact a wide range of other cancer types.

Keywords: breast cancer; cell differentiation; epithelial‑mesenchymal interaction; neutralizing antibody; tumor microenvironment.

MeSH terms

  • Antigens, Surface
  • Breast Neoplasms* / drug therapy
  • Breast Neoplasms* / genetics
  • Breast Neoplasms* / metabolism
  • Cancer-Associated Fibroblasts* / metabolism
  • Cell Line, Tumor
  • Female
  • Fibroblasts / metabolism
  • Humans
  • Keratins / genetics
  • Keratins / metabolism
  • MCF-7 Cells
  • Melanoma, Cutaneous Malignant
  • Milk Proteins / genetics
  • Milk Proteins / metabolism
  • Prognosis
  • Transcriptome
  • Tumor Microenvironment / genetics

Substances

  • Antigens, Surface
  • Keratins
  • MFGE8 protein, human
  • Milk Proteins

Grants and funding

The present study was supported by the Operational Programme Research, Development, and Education within the projects: Center for Tumor Ecology-Research of the Cancer Microenvironment Supporting Cancer Growth and Spread (grant no. CZ.02.1.01/0.0/0.0/16_019/0000785) and project National Institute for Cancer Research (Programme EXCELES, grant No. LX22NPO5102)-funded by the European Union-Next Generation EU, and by Charles University project Cooperatio ONCO. The Grant Agency of the Ministry of Education, Science, Research and Sport of the Slovak Republic (grant nos. VEGA-1/0561/18, 1/0319/20, and 1/0455/22), and the Agency for Science and Research (grant nos. APVV-20-0017 and APVV-22-0006) are also appreciated for support. The study was also supported by the project ‘Open scientific community for modern interdisciplinary research in medicine (OPENMED)’, ITMS2014+: 313011V455 and ‘Long-term strategic research of prevention, intervention and mechanisms of obesity and its comorbidities’, IMTS: 313011V344, Operational Programme Integrated Infrastructure, co-financed by the European Regional Development Fund.